The results showed that about 27.6% of patients with HR+/HER2−, 5.2% of patients with HR+/HER2+, 1.6% of patients with HR-/HER2+, 3.2% of patients with HR-/HER2− only had bone metastasis. The gene discussed is ERBB2; the disease is bone metastasis.